Subarachnoid haemorrhage adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 10,040 adverse event reports that record the MedDRA preferred term Subarachnoid haemorrhage. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 476 reports in the 12 months to June 2026 and 471 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,014 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 476 (under 0.1%) record this term. Reports for patients 75 and over were 25.9% of the reports that record this term and 9.5% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 118 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Subarachnoid haemorrhage name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		85
Acetylsalicylic Acid		229
Actemra	Interleukin-6 receptor antagonist	39
Actilyse		44
Activase		27
Allopurinol	Xanthine oxidase inhibitor	33
Alteplase		90
Amiodarone		30
Amlodipine	Calcium channel blocker	40
Apixaban	Factor Xa inhibitor	678
Aspirin	Nonsteroidal anti-inflammatory drug	572
Astrazeneca Covid-19 Vaccine		344
Atorvastatin		65
Avandia		26
Avastin	Vascular endothelial growth factor inhibitor	66
Avonex	Interferon beta	29
Bayaspirin		26
Bevacizumab	Vascular endothelial growth factor inhibitor	40
Bisoprolol	beta-Adrenergic blocker	121
Bisoprolol fumarate	beta-Adrenergic blocker	365
Brilinta	P2Y12 platelet inhibitor	29
Candesartan	Angiotensin 2 receptor blocker	299
Candesartan cilexetil	Angiotensin 2 receptor blocker	190
Carboplatin	Platinum-based drug	76
Carvedilol	alpha-Adrenergic blocker	28
Cetirizine	Histamine-1 receptor antagonist	198
Cetirizine hydrochloride	Histamine-1 receptor antagonist	293
Cholecalciferol		28
Ciprofloxacin	Fluoroquinolone antibacterial	33
Cisplatin	Platinum-based drug	47
Citalopram	Serotonin reuptake inhibitor	48
Clopidogrel	P2Y12 platelet inhibitor	339
Clopidogrel bisulfate	P2Y12 platelet inhibitor	52
Cordarone		32
Coumadin		110
Coumadine		34
Cyclophosphamide	Alkylating drug	90
Cyclosporine	Calcineurin inhibitor immunosuppressant	37
Cytarabine	Nucleoside metabolic inhibitor	117
Dabigatran		39
Dabigatran etexilate mesylate	Direct thrombin inhibitor	26
Dapagliflozin	Sodium-Glucose cotransporter 2 inhibitor	393
Dexamethasone	Corticosteroid	108
Digoxin	Cardiac glycoside	444
Doxorubicin	Anthracycline topoisomerase inhibitor	34
Effient	P2Y12 platelet inhibitor	32
Eliquis	Factor Xa inhibitor	376
Enbrel	Tumor necrosis factor blocker	61
Enoxaparin sodium	Low molecular weight heparin	29
Escitalopram	Serotonin reuptake inhibitor	38
Esomeprazole	Proton pump inhibitor	301
Esomeprazole magnesium	Proton pump inhibitor	85
Etoposide	Topoisomerase inhibitor	87
Felodipine	Dihydropyridine calcium channel blocker	388
Fluorouracil	Nucleoside metabolic inhibitor	32
Fluoxetine	Serotonin reuptake inhibitor	56
Furosemide	Loop diuretic	62
Heparin		166
Heparin sodium	Anti-coagulant	76
Humira		103
Hydrochlorothiazide	Thiazide diuretic	430
Hydroxyzine	Antihistamine	26
Ibrutinib (form s4)	Kinase inhibitor	29
Ibuprofen	Nonsteroidal anti-inflammatory drug	62
Imbruvica	Kinase inhibitor	48
Imdur		381
Isosorbide	Nitrate vasodilator	36
Isosorbide dinitrate	Nitrate vasodilator	391
Isosorbide mononitrate	Nitrate vasodilator	407
Kardegic		87
Keytruda	Programmed death Receptor-1 blocking antibody	43
Lansoprazole	Proton pump inhibitor	439
Lasix	Loop diuretic	25
Levothyroxine		62
Levothyroxine sodium	l-Thyroxine	385
Linagliptin	Dipeptidyl peptidase 4 inhibitor	432
Lovenox	Low molecular weight heparin	40
Metformin	Biguanide	27
Methotrexate	Folate analog metabolic inhibitor	114
Methylprednisolone	Corticosteroid	83
Metoprolol	beta-Adrenergic blocker	69
Mirtazapine		31
Mycophenolate mofetil	Antimetabolite immunosuppressant	84
Naproxen	Nonsteroidal anti-inflammatory drug	401
Nuvaring	Estrogen	37
Omeprazole	Proton pump inhibitor	84
Opsumit	Endothelin receptor antagonist	28
Oxaliplatin	Platinum-based drug	28
Pantoprazole	Proton pump inhibitor	26
Plavix	P2Y12 platelet inhibitor	156
Pradaxa	Direct thrombin inhibitor	369
Prazaxa		39
Prednisolone	Corticosteroid	115
Prednisone	Corticosteroid	129
Previscan		33
Ramipril	Angiotensin converting enzyme inhibitor	46
Rebetol		37
Revlimid	Thalidomide analog	40
Ribavirin	Nucleoside analog antiviral	29
Rituximab	CD20-directed cytolytic antibody	95
Rivaroxaban	Factor Xa inhibitor	107
Sertraline	Serotonin reuptake inhibitor	71
Sildenafil	Phosphodiesterase 5 inhibitor	34
Simvastatin	HMG-CoA reductase inhibitor	426
Spironolactone	Aldosterone antagonist	54
Tacrolimus	Calcineurin inhibitor immunosuppressant	151
Tenecteplase		26
Ticagrelor	P2Y12 platelet inhibitor	61
Tramadol		40
Valsartan	Angiotensin 2 receptor blocker	25
Venlafaxine	Serotonin and norepinephrine reuptake inhibitor	35
Vincristine		52
Vioxx		58
Warfarin	Vitamin K antagonist	256
Warfarin sodium	Vitamin K antagonist	139
Xarelto	Factor Xa inhibitor	688
Yasmin		26
Zocor	HMG-CoA reductase inhibitor	47

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 44 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Subarachnoid haemorrhage name, in order of name
Class	Reports with this term
Aldosterone antagonist	64
Alkylating drug	151
Angiotensin 2 receptor blocker	569
Angiotensin converting enzyme inhibitor	78
Anthracycline topoisomerase inhibitor	78
Anti-coagulant	106
Antimetabolite immunosuppressant	100
Atypical antipsychotic	105
Benzodiazepine	71
beta-Adrenergic blocker	572
Calcineurin inhibitor immunosuppressant	238
Cardiac glycoside	444
CD20-directed cytolytic antibody	97
Corticosteroid	484
Dihydropyridine calcium channel blocker	396
Dipeptidyl peptidase 4 inhibitor	439
Direct thrombin inhibitor	398
Factor Xa inhibitor	1,894
Folate analog metabolic inhibitor	141
Histamine-1 receptor antagonist	506
HMG-CoA reductase inhibitor	506
Interleukin-6 receptor antagonist	51
Kinase inhibitor	249
l-Thyroxine	385
Loop diuretic	103
Low molecular weight heparin	69
Nitrate vasodilator	845
Nonsteroidal anti-inflammatory drug	1,120
Nucleoside metabolic inhibitor	235
Opioid agonist	66
P2Y12 platelet inhibitor	683
Phosphodiesterase 5 inhibitor	74
Platinum-based drug	151
Programmed death Receptor-1 blocking antibody	94
Proton pump inhibitor	976
Serotonin and norepinephrine reuptake inhibitor	88
Serotonin reuptake inhibitor	293
Sodium-Glucose cotransporter 2 inhibitor	405
Thalidomide analog	79
Thiazide diuretic	430
Topoisomerase inhibitor	103
Tumor necrosis factor blocker	120
Vascular endothelial growth factor inhibitor	132
Vitamin K antagonist	395

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Subarachnoid haemorrhage, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Subarachnoid haemorrhage
Age	Reports	Share
Under 2	30	0.3%
2 to 11	79	0.8%
12 to 17	69	0.7%
18 to 44	1,172	11.7%
45 to 64	2,427	24.2%
65 to 74	1,651	16.4%
75 and over	2,605	25.9%
Age not given	2,007	20%

Sex of the patient in the reports that record Subarachnoid haemorrhage
Sex	Reports	Share
Female	5,005	49.9%
Male	4,101	40.8%
Unknown or not given	934	9.3%

Age and sex are as the report gives them. 36.7% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Subarachnoid haemorrhage: adverse event reports that record this term. https://reportedreactions.com/reaction/subarachnoid-haemorrhage/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Subarachnoid haemorrhage mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page